Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00441155 · ClinicalTrials.gov registry record · Phase 1
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
A Phase 1 study of Gastrointestinal Stromal Tumors, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 4
- Study locations
NCT00441155 is a Phase 1 study of Gastrointestinal Stromal Tumors that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 14 participants, below the 94-participant average among 10 other Gastrointestinal Stromal Tumors trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00441155, a Phase 1 study of Gastrointestinal Stromal Tumors, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 4
- Study locations
Study Summary
To provide study drug to patients that benefit from treatment judged by the investigator - to obtain additional long-term safety and efficacy data of this combination regimen in GIST
Conditions Studied
Interventions
- DRUG Nilotinib, Imatinib
Study Locations (4)
Massachusetts
- Dana Farber Cancer Institute - Boston
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Other
- Novartis Investigative Site - Lyon
MI
- Novartis Investigative Site - Milan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-11 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00441155
The ClinicalTrials.gov registry entry for NCT00441155 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 10 other Gastrointestinal Stromal Tumors trials with a reported enrollment target (85% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastrointestinal Stromal Tumors appearing as the primary indexed condition, and to 1 intervention - of which Nilotinib, Imatinib is the first listed.
NCT00441155 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Pennsylvania, Other.
Frequently Asked Questions
What is clinical trial NCT00441155 about?
NCT00441155 is a clinical study titled "Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib". To provide study drug to patients that benefit from treatment judged by the investigator - to obtain additional long-term safety and efficacy data of this combination regimen in GIST
What is the current status of trial NCT00441155?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2006-11. Estimated completion is 2011-01.
What conditions does trial NCT00441155 study?
This clinical trial studies the following conditions: Gastrointestinal Stromal Tumors.
What interventions are being tested in trial NCT00441155?
The interventions under investigation include: Nilotinib, Imatinib (DRUG).
Who is sponsoring clinical trial NCT00441155?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00441155 being conducted?
This trial has 4 study locations across Massachusetts, Pennsylvania, MI. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Stromal Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
COMPLETED · Phase 1
-
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
RECRUITING · Phase 2
-
Integrated Cancer Repository for Cancer Research
RECRUITING
-
Imatinib TDM in GIST
RECRUITING · Phase 2
-
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.